The Latest Cardiac and Vascular News
ALAMEDA, Calif., May 3, 2022 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2022. Revenue of $203.9 million in the first quarter of 2022, an increase of 20.5%, or 21.8% in constant currency1, compared to the first quarter of […]
Initiated Next Phase of European Expansion Strategy with First National Reimbursement in Sweden Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets Continued Progress on Go-To-Market Strategy in the US Plans for Regulatory Filings for Approval of VASCEPA® (icosapent ethyl) in Several Additional Countries in 2022 Company to […]
Denmark’s only robotic cardiac electrophysiology team is recognized for leading the world in treating the most heart rhythm patients using Stereotaxis’ advanced robotic technology ST. LOUIS, May 04, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, celebrates the achievements of the […]
PARIS, May 04, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat difficult-to-treat/resistant hypertension and heart failure, announces it is strengthening its leadership team with the appointment of Sarah Merlen-Boulenger as Head […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2022. Financial Summary and Highlights1 Worldwide sales were $240.2 million, a decrease of 3.0 percent on a reported basis and 0.3 percent on a constant-currency basis, as compared to […]
PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, today discloses the total number of voting rights and shares as of April 30, 2022 (pursuant to Article L. 233-8 II of the French […]
First Quarter 2022 Highlights Revenue was $304 million; GAAP net income per diluted share was $0.81; and Non-GAAP net income per diluted share was $0.93. IRVINE, Calif.–(BUSINESS WIRE)–Masimo (Nasdaq: MASI) today announced its financial results for the first quarter of 2022, ended April 2, 2022. First Quarter 2022 Results Revenue […]
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2022. Total revenue in the first quarter of 2022 grew 22% year-over-year to $461.9 million, compared to $379.1 million in the first […]
– Synchron and Mount Sinai Hospital in New York Advance Industry-First FDA-Approved Clinical Trial for Brain-Computer Interface in U.S. – Paralysis is a devastating condition for more than 5 million patients in the United States NEW YORK & MELBOURNE, Australia–(BUSINESS WIRE)–Synchron, an endovascular brain-computer (BCI) interface company, today announced the enrollment of […]
More than 60 million magnetic resonance imaging (MRI) scans are performed worldwide each year, but imaging for the millions of patients with cardiac implantable electronic devices (CIEDs) such as pacemakers is a logistical challenge, because of concerns with how the magnetic field affects the implants. Now, a newly published study […]
